Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025
Economic Evaluation of the HEARTS Standardized Hypertension Treatment Program With Fixed-Dose Combination Pills in Chile Primary Care Clinics.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Michea Luis, Kim Thomas T, Hutchinson Brian, Toro Luis, Escobar Maria C, Basu Soumava, Husain Muhammad Jami, Moran Andrew E, Ordunez Pedro, Kostova Deliana, Chile HEARTS Collaborative Group
Аннотация
OBJECTIVES: In 2016, Chile implemented a pilot project in 2 Santiago-area family health centers aimed at improving hypertension control using the HEARTS framework for cardiovascular disease prevention. The core intervention replaced nonstandardized, single-medication regimens with standardized treatment using fixed-dose combination pills. Although prior studies demonstrate improved blood pressure control with fixed-dose combination pills, evidence on cost-effectiveness is essential for scalability.
METHODS: A 10-year outcomes-based Markov model was used to assess the benefits and costs of the HEARTS approach versus usual care from a societal perspective. Incremental program costs were estimated via activity-based costing, and incremental benefits from reductions in acute CVD events. The cost-effectiveness was quantified using incremental benefit-cost ratios and incremental cost per averted disability-adjusted life-year.
RESULTS: Although the HEARTS approach led to higher initial medication costs, averted CVD events generated net savings over time. The incremental benefit-cost ratio was estimated to exceed 1 by year 2 and reached 7.8 by year 10, showing that incremental benefits would exceed costs at an increasing rate over time. The cost per disability-adjusted life-year averted in model year 10 was approximately $2171, demonstrating high cost-effectiveness compared with the per-capita gross domestic product threshold.
CONCLUSIONS: The HEARTS approach in Chile, which uses a standardized hypertension treatment protocol with fixed-dose combination pills, was estimated to be highly cost-effective compared with usual care. It generates substantial net savings over time from estimated reductions in the incidence of acute cardiovascular disease events.
METHODS: A 10-year outcomes-based Markov model was used to assess the benefits and costs of the HEARTS approach versus usual care from a societal perspective. Incremental program costs were estimated via activity-based costing, and incremental benefits from reductions in acute CVD events. The cost-effectiveness was quantified using incremental benefit-cost ratios and incremental cost per averted disability-adjusted life-year.
RESULTS: Although the HEARTS approach led to higher initial medication costs, averted CVD events generated net savings over time. The incremental benefit-cost ratio was estimated to exceed 1 by year 2 and reached 7.8 by year 10, showing that incremental benefits would exceed costs at an increasing rate over time. The cost per disability-adjusted life-year averted in model year 10 was approximately $2171, demonstrating high cost-effectiveness compared with the per-capita gross domestic product threshold.
CONCLUSIONS: The HEARTS approach in Chile, which uses a standardized hypertension treatment protocol with fixed-dose combination pills, was estimated to be highly cost-effective compared with usual care. It generates substantial net savings over time from estimated reductions in the incidence of acute cardiovascular disease events.